Mutations in KRAS have recently become established as a negative predictive marker for the benefit of EGFR monoclonal antibodies in advanced colorectal cancer (Amado et al, 2008; Van Cutsem et al, 2009). The gene discussed is KRAS; the disease is colorectal cancer.